Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Conditions
Hypercholesterolemia, LDL Cholesterol
Interventions
LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Conditions
Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
5,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
Recruiting Phase 4 Interventional

DESIFOR-EXPAND (MHIF)

NCT06804980
Conditions
Statin Therapy, Statin Adverse Reaction, Statin
Interventions
Rosuvastatin (Crestor), Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more
Conditions
Hypercholesterolemia
Interventions
Secura then Futura, Futura then Secura
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hartford, Connecticut • Kansas City, Kansas
Conditions
Cardiovascular Disease, Dyslipidemia, Blood Pressure
Interventions
Dietary Intervention
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Berkeley, California
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Conditions
Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions
VERVE-102, Placebo
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
DeSoto, Texas
Conditions
Prostate Cancer
Interventions
Vytorin, Ezetimibe
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers

The Cholesterol Lowering Effects of Strawberry

NCT02612090
Conditions
Hypercholesterolemia, Glycemic Response
Interventions
Active Treatment Beverage, Placebo Treatment Beverage
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
40 Years to 69 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
lerodalcibep 300 mg Monthly SC
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Conditions
Hyperlipidemia
Interventions
Evacetrapib, Atorvastatin, Ezetimibe, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
61
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
Conditions
LDL Cholesterol
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio
Conditions
Cholesterol Lowering
Interventions
Sugar Pill, Chinese Red Yeast Rice (CRYR), CRYR + TRF, Tocotrienol-enriched Fraction of Palm Oil (TRF)
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

NCT04369664
Conditions
Type 2 Diabetes
Interventions
Statin, PCSK9 inhibitor, Ezetimibe 10mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Familial Hypercholesterolemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
Conditions
Dyslipidemia
Interventions
Motivational Interviewing (MINT), Usual Care
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Alzheimer Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Institute for the Study of Aging (ISOA)
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Sun City, Arizona
Conditions
Hypercholesterolaemia
Interventions
Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more
Conditions
Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Interventions
VERVE-102
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
Conditions
Hyperlipemia, Mixed, ASCVD
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts